Clinical Deep-Dive · Dermatology

Deucravacitinib (SOTYKTU): Clinical Deep‑Dive in Plaque Psoriasis

August 20, 2026

Indication

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; active psoriatic arthritis in adults [1][2][3].

Recommended dose

6 mg orally once daily, with or without food [1][2][3].

POETYK PSO-1 sPGA 0/1 Week 16

Deucravacitinib 54% versus Placebo 7% (POETYK PSO-1) [4].

Randomized population (POETYK PSO-1 and PSO-2)

1,681 subjects randomized across Trials PSO-1 and PSO-2 (840 to deucravacitinib, 419 to placebo, 422 to apremilast) [1][2].

Infection rate (16-week placebo-controlled period)

Infections occurred in 29% of SOTYKTU group vs 22% of placebo group (116 vs 83.7 events per 100 patient-years) [1].

Clinical Perspective

Dermatologists and clinicians treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy may consider the oral TYK2 inhibitor deucravacitinib as an FDA‑labeled systemic option for this population based on the POETYK phase 3 program and the product labeling ^[1]^[2]^[3]^[4]. The phase 3 trials demonstrated sPGA 0/1 responses and PASI improvements at Week 16 with early onset of effect reported as soon as Week 1 for PASI measures and maintenance of response through Week 52 in continuous treatment cohorts ^[4]^[5]^[6]. What remains unanswered in the provided source excerpts is how deucravacitinib compares directly in head-to-head randomized trials versus IL-17, IL-23, or TNF inhibitor biologics in the same populations and with standardized comparative endpoints?

Dr. Rohan Gupta, MBBS, MD (Dermatology, Venereology & Leprosy) · Dermatology

Deucravacitinib (SOTYKTU) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy ^[1]^[2]^[3]^[4]. The FDA-approved dosing is 6 mg taken orally once daily, with or without food ^[1]^[2]^[3]. Clinicians should consult current prescribing information for full dosing guidance. Two pivotal phase 3 trials (POETYK PSO-1 and PSO-2) provided the controlled efficacy and safety data that supported approval and labeling statements about onset, maintenance of effect through 52 weeks, and safety signals observed in the trials ^[4]^[5]^[6].

Clinical Context

Deucravacitinib (SOTYKTU) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and the label also includes an indication for active psoriatic arthritis in adults ^[1]^[2]^[3]. The product labeling warns that SOTYKTU is not recommended for use in combination with other potent immunosuppressants and that patients should be evaluated for active and latent tuberculosis prior to initiating therapy ^[1]^[2]. The prescribing information and FDA materials emphasize the need for baseline and periodic laboratory evaluation for triglycerides and liver enzymes in patients with known or suspected liver disease, and note potential risks observed with JAK inhibitors in a separate RA safety trial that may be relevant to TYK2 inhibition ^[1]^[2]. Detailed comparative data versus IL-17, IL-23, or TNF inhibitors are not reported in the provided source excerpts.

Key Findings

The POETYK PSO-1 trial showed that deucravacitinib achieved a static Physician’s Global Assessment (sPGA) response of 0/1 (clear or almost clear) of 54% versus 7% with placebo at Week 16 in the analysed population (POETYK PSO-1: SOTYKTU N=330, 178 patients with sPGA 0/1; placebo N=166, 12 patients with sPGA 0/1) ^[4].
In POETYK PSO-1 the apremilast comparator arm achieved sPGA 0/1 of 32% at Week 16 (apremilast N=168; 54 patients) and deucravacitinib’s difference from placebo was 47% (95% CI 40, 53) and difference from apremilast was 22% (95% CI 13, 30) for sPGA 0/1 at Week 16 in that trial dataset ^[4].
In the pooled phase 3 program (Trials PSO-1 and PSO-2), a total of 1,681 subjects were randomized to receive deucravacitinib 6 mg once daily, placebo, or apremilast; among randomized subjects, 840 received deucravacitinib, 419 received placebo, and 422 received apremilast in the placebo- and active-controlled periods described in the label ^[1]^[2].
Clinicians should consult current prescribing information for full dosing guidance.
Onset and durability: an analysis of POETYK PSO-1 and PSO-2 reported that deucravacitinib showed significantly higher mean percent change from baseline in PASI versus placebo by Week 1, with significant improvement versus placebo observed by Week 8 across multiple efficacy measures and efficacy maintained through Week 52 in patients treated continuously with deucravacitinib ^[5].
Patients who switched from apremilast to deucravacitinib after inadequate response demonstrated clinically meaningful improvements: in patients who switched, PASI 75 response rates improved from 0% at Week 24 to 46.3% (PSO-1) and 42.3% (PSO-2) at Week 52 in the POETYK analyses of apremilast nonresponders who crossed to deucravacitinib ^[7].
Laboratory and long-term safety datasets: pooled safety analyses from the two phase 3 trials reported that adverse event incidence rates were similar across treatment groups over 52 weeks and that no new safety signals emerged with longer treatment; total pooled enrollment for the safety analyses included 1,683 patients with exposure-adjusted rates reported for events of interest (for example, serious infections, major adverse cardiovascular events, venous thromboembolic events, malignancies, herpes zoster, acne, and folliculitis) ^[6].

Safety & Tolerability

In the 16-week placebo-controlled period of Trials PSO-1 and PSO-2, adverse reactions occurring in ≥1% of subjects in the SOTYKTU group and at a higher rate than placebo included: upper respiratory infections 161/840 (19.2%) versus 62/419 (14.8%) ^[1].
Blood creatine phosphokinase increased occurred in 23/840 (2.7%) of SOTYKTU-treated subjects versus 5/419 (1.2%) with placebo ^[1].
Herpes simplex infections were reported in 17/840 (2.0%) of SOTYKTU-treated subjects versus 1/419 (0.2%) with placebo in the 16-week controlled period; herpes zoster was reported at <1% in SOTYKTU-treated subjects ^[1].
Mouth ulcers were reported in 16/840 (1.9%) of SOTYKTU-treated subjects versus 0/419 (0.0%) with placebo ^[1].
Folliculitis occurred in 14/840 (1.7%) of SOTYKTU subjects versus 0/419 (0.0%) with placebo, and acne occurred in 12/840 (1.4%) versus 1/419 (0.2%) with placebo ^[1].
Infections overall occurred in 29% of subjects in the SOTYKTU group (116 events per 100 patient-years) compared to 22% of subjects in the placebo group (83.7 events per 100 patient-years) during the 16-week placebo-controlled period ^[1].
Serious infections in the 16-week period were reported in 5 subjects treated with SOTYKTU (2.0 per 100 patient-years) and 2 subjects treated with placebo (1.6 per 100 patient-years); the most common serious infections reported during the 52‑week treatment period were pneumonia and COVID-19 ^[1].
Pooled 52-week exposure-adjusted incidence rates reported in the phase 3 safety pooled analysis included: serious infections 1.7/100 person-years with deucravacitinib versus 0.8/100 person-years with placebo, major adverse cardiovascular events 0.3/100 person-years with deucravacitinib versus 1.2/100 person-years with placebo, venous thromboembolic events 0.2/100 person-years with deucravacitinib versus 0 with placebo, and malignancies 1.0/100 person-years with deucravacitinib versus 0 with placebo ^[6].
The FDA label highlights warnings and precautions including hypersensitivity reactions (including angioedema), infections (including tuberculosis), malignancy including lymphomas, rhabdomyolysis and elevated CPK, laboratory abnormalities (triglycerides and liver enzymes), and immunization considerations; it also advises evaluating patients for TB and completing immunizations according to current guidelines prior to initiation ^[1]^[2]^[3].

Study Design

The regulatory program for deucravacitinib included two pivotal phase 3 trials, POETYK PSO-1 and POETYK PSO-2, that were randomized and included placebo and an active comparator arm with apremilast 30 mg twice daily in the controlled periods reported in the labeling and FDA materials ^[1]^[2]^[4]. Clinicians should consult current prescribing information for full dosing guidance. Trial randomization was 1:2:1 to placebo, deucravacitinib, or apremilast in the described datasets, with 1,681 subjects randomized in Trials PSO-1 and PSO-2 in the label summary (840 subjects randomized to deucravacitinib, 419 to placebo, and 422 to apremilast) ^[1]^[2]. The co‑primary efficacy endpoints specified in the FDA Snapshot and trial summaries were sPGA 0/1 (static Physician’s Global Assessment of 0 or 1 at Week 16) and PASI 75 (≥75% improvement from baseline in Psoriasis Area and Severity Index at Week 16) ^[4]. The trials were conducted with blinded controlled periods through Week 16 and longer-term follow-up to Week 52 for maintenance and safety assessments; extension studies allowed continued exposure and pooled safety analyses ^[1]^[2]^[4]^[6]. Specific statistical analysis plans, multiplicity controls, and predefined noninferiority or superiority hypotheses were described in the trial protocols and regulatory submissions but detailed statistical methods beyond the co-primary endpoint definitions were not included in the provided source excerpts. TRIAL IDENTIFIERS and full protocol statistical plans were not available in the provided source excerpts.

FAQ

Q1 What is deucravacitinib (SOTYKTU) approved for?

Deucravacitinib (SOTYKTU) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and it is also indicated for the treatment of active psoriatic arthritis in adults. The label notes that SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

Q2 How does deucravacitinib work?

Deucravacitinib is an oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the Janus kinase family; it modulates signaling pathways implicated in psoriasis pathophysiology through TYK2 inhibition, as described in the prescribing information and regulatory summaries.

Q3 What is the recommended dose of deucravacitinib (SOTYKTU)?

The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food. The prescribing information states not to crush, cut, or chew the tablets and to follow recommended evaluations and immunization guidance prior to initiation. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the side effects of deucravacitinib reported in trials?

Common adverse reactions reported at ≥1% and more frequent than placebo in the 16-week controlled period included upper respiratory infections, increased blood creatine phosphokinase, herpes simplex, mouth ulcers, folliculitis, and acne. The label also summarizes warnings about infections (including tuberculosis), hypersensitivity reactions, malignancies including lymphomas, rhabdomyolysis and elevated CPK, laboratory abnormalities (triglycerides and liver enzymes), and immunization considerations.

Deucravacitinib (SOTYKTU): Clinical Deep‑Dive in Plaque Psoriasis

Direct Clinical Takeaway & Evidence Summary

Deucravacitinib (SOTYKTU): Clinical Deep‑Dive in Plaque Psoriasis

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Dermatology in your inbox.

Related Clinical Updates

Dupilumab Label Updates 2025: Atopic Dermatitis Indication and Dosing

FDA Approves difamilast for Mild‑Moderate AD: 38% IGA Success in Trial 2

FDA Approves difamilast for Mild‑Mod AD: 38% IGA Success (Trial 2)

Verified HCP Portal